The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis
Abstract
The aim of this study was to provide confirmation that once-weekly dosing with 70 mg of alendronate (seven times the daily oral dose) and twice-weekly dosing with 35 mg is equivalent to the 10-mg once-daily regimen and to gain more extensive safety experience with this new dosing regimen. Twelve hundred fifty-eight postmenopausal women (aged 42–95 years) with osteoporosis (bone mineral density [BMD] of either lumbar spine or femoral neck at least 2.5 SDs below peak young adult mean or prior vertebral or hip fracture) were assigned to receive oral once-weekly alendronate, 70 mg (n = 519); twice-weekly alendronate, 35 mg (n = 369); or daily alendronate 10 mg (n = 370) for a total of 2 years of double-blind experience. Mean BMD increases from baseline (95% CI) at 24 months in the once-weekly, twice-weekly, and daily treatment groups, respectively, were 6.8% (6.4, 7.3), 7.0% (6.6, 7.5), and 7.4% (6.9, 7.8) at the lumbar spine and 4.1% (3.8, 4.5), 4.3% (3.9, 4.7), and 4.3% (3.9, 4.7) at the total hip. These increases in BMD as well as the BMD increases at the femoral neck, trochanter, and total body and the reductions of biochemical markers of bone resorption (urinary cross-linked N-telopeptides of type I collagen [NTx]) and bone formation (serum bone-specific alkaline phosphatase [BSAP]) were similar for the three dosing regimens. All treatment regimens were well tolerated with a similar incidence of upper gastrointestinal (GI) adverse experiences. The incidence rates of clinical fractures, captured as adverse experiences, were similar among the groups. The 2-year results confirm the conclusion reached after 1 year that once-weekly alendronate is therapeutically equivalent to daily dosing, providing patients with a more convenient dosing option that may potentially enhance adherence to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Balena, R., Toolan, B. C., Shea, M., Markatos, A., Myers, E. R., Lee, S. C., Opas, E. E., Seedor, J. G., Klein, H., & Frankenfield, D. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116872 · Cited by 396
Research works printed but not linked: 31
- Greenberg, 1984, Overview of patient compliance with medication dosing: A literature review, Clin Ther, 6, 592
- Lau, 1996, Non-compliance in elderly people: Evaluation of risk factors by longitudinal data analysis, Pharm World Sci, 18, 63, 10.1007/BF00579707 · DOI
- Venturini, 1999, Compliance with sulfonylureas in a health maintenance organization: A pharmacy record-based study, Ann Pharmacother, 33, 281, 10.1345/aph.18198 · DOI
- Liberman, 1995, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis, N Engl J Med, 333, 1437, 10.1056/NEJM199511303332201 · DOI · Paper page
- Black, 1996, Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2 · DOI · Paper page
- Pols, 1999, Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study, Osteoporos Int, 9, 461, 10.1007/PL00004171 · DOI · Paper page
- Hochberg, 1999, Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis, Arthritis Rheum, 42, 1246, 10.1002/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U · DOI · Paper page
- Bauer, 2000, Upper gastrointestinal tract safety profile of alendronate: The Fracture Intervention Trial, Arch Intern Med, 160, 517, 10.1001/archinte.160.4.517 · DOI · Paper page
- Bone, 2000, Weekly administration of alendronate: Rationale and plan for clinical assessment, Clin Ther, 22, 15, 10.1016/S0149-2918(00)87974-6 · DOI
- Schnitzer, 2000, Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis, Aging Clin Exp Res, 12, 1, 10.1007/BF03339822 · DOI · Paper page
- Black, 1995, Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fractures, J Bone Miner Res, 10, 890, 10.1002/jbmr.5650100610 · DOI · Paper page
- Faulkner, 1995, Quality control of DXA instruments in multicenter trials, Osteoporos Int, 5, 218, 10.1007/BF01774010 · DOI
- ICH Harmonised Tripartite Guideline, 1999, Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group, Stat Med, 18, 1905
- Genant, 1993, Vertebral fracture assessment using a semiquantitative technique, J Bone Miner Res, 8, 1137, 10.1002/jbmr.5650080915 · DOI · Paper page
- Black, 2000, Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial, J Clin Endocrinol Metab, 85, 4118, 10.1210/jcem.85.11.6953 · DOI · Paper page
- Thompson, 2000, Consistency of effect of alendronate on reduction in risk of hip fractures, J Am Geriatr Soc, 48, S56
- Faulkner, 2000, Bone matters: Are density increases necessary to reduce fracture risk?, J Bone Miner Res, 15, 183, 10.1359/jbmr.2000.15.2.183 · DOI · Paper page
- Garnero, 1996, Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study, J Bone Miner Res, 11, 1531, 10.1002/jbmr.5650111021 · DOI · Paper page
- Riis, 1996, Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture: A 15-year follow-up study, Bone, 19, 9, 10.1016/8756-3282(96)00102-0 · DOI · Paper page
- Harris, 1993, Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy, Am J Med, 95, 557, 10.1016/0002-9343(93)90350-X · DOI · Paper page
- Recker, 2000, A new treatment paradigm: Quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): Results of a 3-year trial, Osteoporos Int, 11, S209
- Chesnut, 1995, Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling, Am J Med, 99, 144, 10.1016/S0002-9343(99)80134-X · DOI · Paper page
- Devogelaer, 1996, Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis, Bone, 18, 141, 10.1016/8756-3282(95)00436-X · DOI · Paper page
- Adami, 1995, Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis, Bone, 17, 383, 10.1016/S8756-3282(95)00262-6 · DOI
- Garnero, 1994, Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment, J Clin Endocrinol Metab, 79, 1693
- Bone, 2002, Once-weekly alendronate 70 mg: Sustained suppression of bone resorption, Osteoporos Int, 13, S29
- Chavassieux, 1997, Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis, J Clin Invest, 100, 1475, 10.1172/JCI119668 · DOI · Paper page
- Seedor, 1991, The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats, J Bone Miner Res, 6, 339, 10.1002/jbmr.5650060405 · DOI · Paper page
- DeGroen, 1996, Esophagitis associated with the use of alendronate, N Engl J Med, 335, 1016, 10.1056/NEJM199610033351403 · DOI · Paper page
- Reginster, 2000, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis, Osteoporos Int, 11, 83, 10.1007/s001980050010 · DOI · Paper page
- Peter, 1998, Esophageal irritation due to alendronate sodium tablets: Possible mechanisms, Dig Dis Sci, 43, 1998, 10.1023/A:1018894827961 · DOI
Cited by
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945
Bisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
Interventions for enhancing medication adherence
Haynes, R. B., Ackloo, E., Sahota, N., McDonald, H. P., & Yao, X. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub3 · Cited by 1,244
IOF Fracture Working Group, Åkesson, K., Marsh, D., Mitchell, P. J., McLellan, A. R., Stenmark, J., Pierroz, D. D., Kyer, C., & Cooper, C. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2348-z · Cited by 521
Interventions for enhancing medication adherence
Haynes, R., Yao, X., Degani, A., Kripalani, S., Garg, A., & McDonald, H. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub2 · Cited by 517
Metadata
- Authors
- The Alendronate Once-Weekly Study Group, & Rizzoli, R.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-11-01
- Volume
- 17
- Issue
- 11
- Pages
- 1988-1996
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2126162095
- Cited by
- 221
- References
- 2
- FWCI
- 19.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis. https://app.cochat.ai/papers/10.1359/jbmr.2002.17.11.1988
- The paper
- The Alendronate Once-Weekly Study Group, & Rizzoli, R. (2002). Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.2002.17.11.1988
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.